In the context of cancer, tumor cells strategically employ immune checkpoint molecules, exemplified by the PD-1 ligand (PD-L1), as mechanisms to suppress the activity of T cells, consequently facilitating immune evasion. This evidence concerns the gene CD274 and cancer.